Northwest Biotherapeutics, Inc. NWBO · Stock Open Northwest Biotherapeutics, Inc. in new tab
Northwest Biotherapeutics, Inc. Analysis (NWBO)
Is Northwest Biotherapeutics, Inc. a good investment? Northwest Biotherapeutics, Inc. (NWBO) is currently trading at 0.1510 USD.
Earnings Schedule: Northwest Biotherapeutics, Inc. is expected to release its next earnings report on Nov. 12, 2026. The market consensus estimate for Forward EPS is -0.07.
Investor FAQ
Does Northwest Biotherapeutics, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Northwest Biotherapeutics, Inc.?
Northwest Biotherapeutics, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Nov. 12, 2026. The company currently has a trailing EPS of -0.03.
Company Profile
Northwest Biotherapeutics, Inc., a biotechnology company, engages in the development of personalized immune therapies for cancer. The company develops DCVax, a platform technology which uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. It also engages in the development of its lead product candidate DCVax-L in Phase III trials for glioblastoma multiforme brain cancer. In addition, the company develops DCVax-Direct in Phase I trials to treat inoperable solid tumors. Northwest Biotherapeutics, Inc. was founded in 1996 and is headquartered in Bethesda, Maryland.
| Split Date | Split Ratio to 1 |
|---|---|
| June 28, 2007 | 0.07 |
| Sept. 26, 2012 | 0.06 |
Community Discussion